Описание
Ход выполнения
Заболевания
Дата начала КИ
18.07.2018
Дата окончания КИ
18.04.2021
Организация, проводящая КИ
Adamas Pharmaceuticals, Inc.
Фаза КИ
III
Цель КИ
This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
Количество пациентов
424
Источник